U.S. markets open in 6 hours 19 minutes

Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (the “Company”) (CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Patrick Trojer has been appointed Chief Scientific Officer, effective immediately. 

Dr. Trojer joined Constellation Pharmaceuticals, Inc. (the “Company” or “Constellation”) as a founding scientist in 2008, working closely with the initial investors—The Column Group, Third Rock Ventures, and Venrock—to launch the Company.  He has held positions of increasing responsibility at Constellation, initially leading biology, then research and, most recently, as senior vice president, EZH2 franchise and head of translational sciences.  During his tenure at Constellation, he has built a strong scientific team to generate innovative cancer therapeutics by targeting various gene regulatory (epigenetic) mechanisms.  He made a significant contribution to building Constellation’s portfolio of two clinical and multiple preclinical product candidates.  With over 20 years of experience in epigenetics and transcription and a distinguished publication record, Dr. Trojer has become a cancer epigenetics thought leader.  Dr. Trojer received a Ph.D. in protein biochemistry and molecular biology from the Leopold Franzens University in Innsbruck, Austria.  He completed his postdoctoral studies at NYU Medical School in the laboratory of Dr. Danny Reinberg, a Constellation founder. 

“I’m delighted to announce Patrick’s appointment as Chief Scientific Officer,” said Jigar Raythatha, CEO of Constellation.  “His depth of knowledge in epigenetics and his experience in translational sciences have been invaluable in advancing Constellation’s product pipeline.  We look forward to his continuing leadership as we work to bring several innovative drug candidates to cancer patients in need.”

“I am honored to serve as Constellation’s Chief Scientific Officer,” said Dr. Trojer.  “In our ten-year history, we have grown from a small group of pioneering scientists into one of the leading drug discovery and development organizations in cancer epigenetics.  I look forward to helping to advance our pipeline of clinical programs and leading the discovery of novel drug candidates from our cancer epigenetics platform.”

About Constellation Pharmaceuticals, Inc.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.  The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance.  Constellation is driving development of the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers as well as the BET inhibitor CPI-0610 for the treatment of myelofibrosis.  The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.         

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status and potential benefit of the Company’s product candidates.  All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company’s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission.


Ronald Aldridge
Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060